|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Edwards BK, Ward E, Kohler BA, Eheman C,
Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I,
Seeff LC, van Ballegooijen M, Goede SL and Ries LA: Annual report
to the nation on the status of cancer, 1975–2006, featuring
colorectal cancer trends and impact of interventions (risk factors,
screening, and treatment) to reduce future rates. Cancer.
116:544–573. 2010.
|
|
3
|
Kirkali Z, Chan T, Manoharan M, Algaba F,
Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM,
Sesterhenn IA, Tachibana M and Weider J: Bladder cancer:
epidemiology, staging and grading, and diagnosis. Urology. 66:4–34.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Heney NM: Natural history of superficial
bladder cancer. Prognostic features and long-term disease course.
Urol Clin North Am. 19:429–433. 1992.PubMed/NCBI
|
|
5
|
Bellmunt J and Guix M: New agents for
bladder cancer. Ann Oncol. 21(Suppl 7): vii56–58. 2010. View Article : Google Scholar
|
|
6
|
Pawinski A, Sylvester R, Kurth KH,
Bouffioux C, van der Meijden A, Parmar MK and Bijnens L: A combined
analysis of European Organization for Research and Treatment of
Cancer, and Medical Research Council randomized clinical trials for
the prophylactic treatment of stage TaT1 bladder cancer. European
Organization for Research and Treatment of Cancer Genitourinary
Tract Cancer Cooperative Group and the Medical Research Council
Working Party on Superficial Bladder Cancer. J Urol. 156:1934–1940.
1996.
|
|
7
|
Sylvester RJ, Oosterlinck W and van der
Meijden AP: A single immediate postoperative instillation of
chemotherapy decreases the risk of recurrence in patients with
stage Ta T1 bladder cancer: a meta-analysis of published results of
randomized clinical trials. J Urol. 171:2186–2190; quiz 2435. 2004.
View Article : Google Scholar
|
|
8
|
Sengupta S and Blute ML: The management of
superficial transitional cell carcinoma of the bladder. Urology.
67:48–54. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dovedi SJ and Davies BR: Emerging targeted
therapies for bladder cancer: a disease waiting for a drug. Cancer
Metastasis Rev. 28:355–367. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Teramura M, Kobayashi S, Yoshinaga K,
Iwabe K and Mizoguchi H: Effect of interleukin 11 on normal and
pathological thrombopoiesis. Cancer Chemother Pharmacol.
38:S99–S102. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
von Rango U, Alfer J, Kertschanska S, Kemp
B, Muller-Newen G, Heinrich PC, Beier HM and Classen-Linke I:
Interleukin-11 expression: its significance in eutopic and ectopic
human implantation. Mol Hum Reprod. 10:783–792. 2004.PubMed/NCBI
|
|
12
|
McKinley D, Wu Q, Yang-Feng T and Yang YC:
Genomic sequence and chromosomal location of human interleukin-11
gene (IL11). Genomics. 13:814–819. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Grosfeld JL, Du X and Williams DA:
Interleukin-11: its biology and prospects for clinical use. JPEN J
Parenter Enteral Nutr. 23:S67–S69. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yap J, Salamonsen LA, Jobling T, Nicholls
PK and Dimitriadis E: Interleukin 11 is upregulated in uterine
lavage and endometrial cancer cells in women with endometrial
carcinoma. Reprod Biol Endocrinol. 8:632010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Furuya Y, Nishio R, Junicho A, Nagakawa O
and Fuse H: Serum interleukin-11 in patients with benign prostatic
hyperplasia and prostate cancer. Int Urol Nephrol. 37:69–71. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sales KJ, Grant V, Cook IH,
Maldonado-Perez D, Anderson RA, Williams AR and Jabbour HN:
Interleukin-11 in endometrial adenocarcinoma is regulated by
prostaglandin F2alpha-F-prostanoid receptor interaction via the
calcium-calcineurin-nuclear factor of activated T cells pathway and
negatively regulated by the regulator of calcineurin-1. Am J
Pathol. 176:435–445. 2010. View Article : Google Scholar
|
|
17
|
Nakayama T, Yoshizaki A, Izumida S,
Suehiro T, Miura S, Uemura T, Yakata Y, Shichijo K, Yamashita S and
Sekin I: Expression of interleukin-11 (IL-11) and IL-11 receptor α
in human gastric carcinoma and IL-11 upregulates the invasive
activity of human gastric carcinoma cells. Int J Oncol. 30:825–833.
2007.
|
|
18
|
Trepicchio WL and Dorner AJ:
Interleukin-11. A gp130 cytokine. Ann NY Acad Sci. 856:12–21. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Du XX and Williams DA: Interleukin-11: a
multifunctional growth factor derived from the hematopoietic
microenvironment. Blood. 83:2023–2030. 1994.PubMed/NCBI
|
|
20
|
Weich NS, Wang A, Fitzgerald M, Neben TY,
Donaldson D, Giannotti J, Yetz-Aldape J, Leven RM and Turner KJ:
Recombinant human interleukin-11 directly promotes
megakaryocytopoiesis in vitro. Blood. 90:3893–3902. 1997.
|
|
21
|
Du X, Everett ET, Wang G, Lee WH, Yang Z
and Williams DA: Murine interleukin-11 (IL-11) is expressed at high
levels in the hippocampus and expression is developmentally
regulated in the testis. J Cell Physiol. 168:362–372. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Musashi M, Yang YC, Paul SR, Clark SC,
Sudo T and Ogawa M: Direct and synergistic effects of interleukin
11 on murine hemopoiesis in culture. Proc Natl Acad Sci USA.
88:765–769. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Musashi M, Clark SC, Sudo T, Urdal DL and
Ogawa M: Synergistic interactions between interleukin-11 and
interleukin-4 in support of proliferation of primitive
hematopoietic progenitors of mice. Blood. 78:1448–1451.
1991.PubMed/NCBI
|
|
24
|
Holyoake TL, Freshney MG, McNair L, Parker
AN, McKay PJ, Steward WP, Fitzsimons E, Graham GJ and Pragnell IB:
Ex vivo expansion with stem cell factor and interleukin-11 augments
both short-term recovery posttransplant and the ability to serially
transplant marrow. Blood. 87:4589–4595. 1996.PubMed/NCBI
|
|
25
|
Yin TG, Schendel P and Yang YC:
Enhancement of in vitro and in vivo antigen-specific antibody
responses by interleukin 11. J Exp Med. 175:211–216. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Elias JA, Tang W and Horowitz MC: Cytokine
and hormonal stimulation of human osteosarcoma interleukin-11
production. Endocrinology. 136:489–498. 1995.PubMed/NCBI
|
|
27
|
Trepicchio WL, Bozza M, Pedneault G and
Dorner AJ: Recombinant human IL-11 attenuates the inflammatory
response through down-regulation of proinflammatory cytokine
release and nitric oxide production. J Immunol. 157:3627–3634.
1996.PubMed/NCBI
|
|
28
|
Kapina MA, Shepelkova GS, Avdeenko VG,
Guseva AN, Kondratieva TK, Evstifeev VV and Apt AS: Interleukin-11
drives early lung inflammation during Mycobacterium tuberculosis
infection in genetically susceptible mice. PLoS One. 6:e21878
|
|
29
|
Sonis S, Muska A, O’Brien J, Van Vugt A,
Langer-Safer P and Keith J: Alteration in the frequency, severity
and duration of chemotherapy-induced mucositis in hamsters by
interleukin-11. Eur J Cancer B Oral Oncol. 31B:261–266. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Du X, Liu Q, Yang Z, Orazi A, Rescorla FJ,
Grosfeld JL and Williams DA: Protective effects of interleukin-11
in a murine model of ischemic bowel necrosis. Am J Physiol.
272:G545–G552. 1997.PubMed/NCBI
|
|
31
|
Castagliuolo I, Kelly CP, Qiu BS,
Nikulasson ST, LaMont JT and Pothoulakis C: IL-11 inhibits
Clostridium difficile toxin A enterotoxicity in rat ileum. Am J
Physiol. 273:G333–G341. 1997.PubMed/NCBI
|
|
32
|
Zheng T, Zhu Z, Wang J, Homer RJ and Elias
JA: IL-11: insights in asthma from overexpression transgenic
modeling. J Allergy Clin Immunol. 108:489–496. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Waxman AB, Einarsson O, Seres T,
Knickelbein RG, Warshaw JB, Johnston R, Homer RJ and Elias JA:
Targeted lung expression of interleukin-11 enhances murine
tolerance of 100% oxygen and diminishes hyperoxia-induced DNA
fragmentation. J Clin Invest. 101:1970–1982. 1998.
|
|
34
|
Putoczki T and Ernst M: More than a
sidekick: the IL-6 family cytokine IL-11 links inflammation to
cancer. J Leukoc Biol. 88:1109–1117. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Michaud DS: Chronic inflammation and
bladder cancer. Urol Oncol. 25:260–268. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hussain SP, Hofseth LJ and Harris CC:
Radical causes of cancer. Nat Rev Cancer. 3:276–285. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ohshima H, Tatemichi M and Sawa T:
Chemical basis of inflammation-induced carcinogenesis. Arch Biochem
Biophys. 417:3–11. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Klaunig JE and Kamendulis LM: The role of
oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol.
44:239–267. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Swana HS, Smith SD, Perrotta PL, Saito N,
Wheeler MA and Weiss RM: Inducible nitric oxide synthase with
transitional cell carcinoma of the bladder. J Urol. 161:630–634.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Egner JR: AJCC Cancer Staging Manual.
JAMA. 304:1726–1727. 2010. View Article : Google Scholar
|
|
42
|
Bartsch G, Mitra AP and Cote RJ:
Expression profiling for bladder cancer: strategies to uncover
prognostic factors. Expert Rev Anticancer Ther. 10:1945–1954. 2010.
View Article : Google Scholar : PubMed/NCBI
|
